Skip to main content

Advertisement

SpringerLink
Log in

Urine chemokines indicate pathogenic association of obesity with BPH/LUTS

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Objectives

High prevalence of lower urinary tract symptoms (LUTS) consistent with benign prostate hyperplasia (BPH) is associated with obesity and prostatic inflammation. Here, we investigated whether chemokines associated with obesity and prostatic inflammation can be measured in normally voided urine of BPH/LUTS patients to demonstrate the mechanistic association between obesity and BPH/LUTS.

Methods

Frozen urine specimens of BPH/LUTS patients enrolled in the Nashville Men’s Health Study were sent for blinded analysis to University of Pittsburgh. Thirty patients were blocked by their AUA-SI (>7 or ≤7) and prostatic enlargement (<40, 40–60, >60 cc). Clinical parameters including age, prostate size, and medications were derived from chart review. CXC chemokines (CXCL-1, CXCL-8, and CXCL-10), CC chemokines (CCL2 and CCL3), and sIL-1ra were measured in thawed urine using Luminex™ xMAP® technology and ELISA for NGF.

Results

Urinary CCL2 levels were several fold higher compared with the other six proteins, of which CCL3 was detectable in less than one-fourth of patients. Urine levels of sIL-1ra and CXCL-8 were significantly associated with increasing BMI and waist circumference in BPH patients. CXCL-8 showed a marginal association with overall AUA-SI scores, as well as obstructive (p = 0.08) symptom subscores. Prostate volume was inversely and marginally associated with urinary CXCL-10 (p = 0.09).

Conclusions

Urine levels of CXCL-8, CXCL-10, and sIL-1ra were associated with varying degrees with LUTS severity, prostate size, and obesity, respectively. These findings in urine are consistent with past studies of chemokine levels from expressed prostatic secretions and demonstrate the potential of noninvasively measured chemokine in urine to objectively classify BPH/LUTS patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Michel M, de la Rosette J (2009) Medical treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Euro Urol Suppl 8(6):496–503

    Article  CAS  Google Scholar 

  2. Roehrborn CG (2008) BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 101(Suppl 3):17–21. doi:10.1111/j.1464-410X.2008.07497.x

    Article  PubMed  Google Scholar 

  3. St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ (2006) Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol 164(8):760–768. doi:10.1093/aje/kwj258

    Article  PubMed  Google Scholar 

  4. Raheem OA, Parsons JK (2014) Associations of obesity, physical activity and diet with benign prostatic hyperplasia and lower urinary tract symptoms. Curr Opin Urol 24(1):10–14. doi:10.1097/MOU.0000000000000004

    Article  PubMed  Google Scholar 

  5. Jiang M, Strand DW, Franco OE, Clark PE, Hayward SW (2011) PPARgamma: a molecular link between systemic metabolic disease and benign prostate hyperplasia. Differentiation 82(4–5):220–236. doi:10.1016/j.diff.2011.05.008

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Li HB, Jin C, Chen Y, Flavell RA (2014) Inflammasome activation and metabolic disease progression. Cytokine Growth Factor Rev 25(6):699–706. doi:10.1016/j.cytogfr.2014.07.020

    Article  CAS  PubMed  Google Scholar 

  7. Perez de Lema G, Maier H, Nieto E, Vielhauer V, Luckow B, Mampaso F, Schlondorff D (2001) Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol 12(7):1369–1382

    CAS  PubMed  Google Scholar 

  8. Macoska JA (2011) Chemokines and BPH/LUTS. Differentiation 82(4–5):253–260. doi:10.1016/j.diff.2011.04.003

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Tyagi P, Killinger K, Tyagi V, Nirmal J, Chancellor M, Peters KM (2012) Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitis. J Urol 187(6):2243–2248. doi:10.1016/j.juro.2012.01.034

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Hung SF, Chung SD, Kuo HC (2014) Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia. PLoS ONE 9(1):e85588. doi:10.1371/journal.pone.0085588

    Article  PubMed Central  PubMed  Google Scholar 

  11. Fujita K, Ewing CM, Getzenberg RH, Parsons JK, Isaacs WB, Pavlovich CP (2010) Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia. Prostate 70(5):473–481. doi:10.1002/pros.21081

    CAS  PubMed  Google Scholar 

  12. Penna G, Mondaini N, Amuchastegui S, Innocenti SD, Carini M, Giubilei G, Fibbi B, Colli E, Maggi M, Adorini L (2007) Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 51(2):524–533 discussion 533

    Article  CAS  PubMed  Google Scholar 

  13. Vignozzi L, Gacci M, Cellai I, Santi R, Corona G, Morelli A, Rastrelli G, Comeglio P, Sebastanelli A, Maneschi E, Nesi G, De Nunzio C, Tubaro A, Mannucci E, Carini M, Maggi M (2013) Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate 73(8):789–800. doi:10.1002/pros.22623

    Article  CAS  PubMed  Google Scholar 

  14. Tyagi P, Chancellor M, Kupelian V, Araujo A, Rosen R, McKinlay J (2011) Obesity, inflammation and overactive bladder: preliminary results from a pilot study of serum leptin and MCP-1 levels in men and women with and without OAB symptoms. J Urol 185(4, Supplement):e462–e463. doi:10.1016/j.juro.2011.02.763

    Article  Google Scholar 

  15. Wei JT, Calhoun E, Jacobsen SJ (2008) Urologic diseases in America project: benign prostatic hyperplasia. J Urol 179(5 Suppl):S75–S80. doi:10.1016/j.juro.2008.03.141

    Article  PubMed  Google Scholar 

  16. Cartier A, Bergeron J, Poirier P, Almeras N, Tremblay A, Lemieux I, Despres JP (2009) Increased plasma interleukin-1 receptor antagonist levels in men with visceral obesity. Ann Med 41(6):471–478. doi:10.1080/07853890903022801

    Article  CAS  PubMed  Google Scholar 

  17. Weber K, Schilling JD (2014) Lysosomes integrate metabolic-inflammatory cross-talk in primary macrophage inflammasome activation. J Biol Chem 289(13):9158–9171. doi:10.1074/jbc.M113.531202

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Konwar R, Gara R, Singh M, Singh V, Chattopadhyay N, Bid HK (2008) Association of interleukin-4 and interleukin-1 receptor antagonist gene polymorphisms and risk of benign prostatic hyperplasia. Urology 71(5):868–872. doi:10.1016/j.urology.2007.12.072

    Article  PubMed  Google Scholar 

  19. Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B, Gessl A, Lee C, Marberger M (2002) Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 52(1):43–58. doi:10.1002/pros.10084

    Article  CAS  PubMed  Google Scholar 

  20. Steiner GE, Stix U, Handisurya A, Willheim M, Haitel A, Reithmayr F, Paikl D, Ecker RC, Hrachowitz K, Kramer G, Lee C, Marberger M (2003) Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest 83(8):1131–1146

    Article  CAS  PubMed  Google Scholar 

  21. Lotti F, Corona G, Colpi GM, Filimberti E, Degli Innocenti S, Mancini M, Baldi E, Noci I, Forti G, Adorini L, Maggi M (2011) Elevated body mass index correlates with higher seminal plasma interleukin 8 levels and ultrasonographic abnormalities of the prostate in men attending an andrology clinic for infertility. J Endocrinol Invest 34(10):e336–e342. doi:10.3275/7855

    CAS  PubMed  Google Scholar 

  22. Antoniou KM, Tzanakis N, Tzortzaki EG, Malagari K, Koutsopoulos AV, Alexandrakis M, Wells AU, Siafakas NM (2008) Different angiogenic CXC chemokine levels in bronchoalveolar lavage fluid after interferon gamma-1b therapy in idiopathic pulmonary fibrosis patients. Pulm Pharmacol Ther 21(6):840–844. doi:10.1016/j.pupt.2008.06.005

    Article  CAS  PubMed  Google Scholar 

  23. Macoska JA, Begley LA, Dunn RL, Siddiqui J, Wei JT, Sarma AV (2008) Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with low total serum PSA. Prostate 68(4):442–452. doi:10.1002/pros.20717

    Article  CAS  PubMed  Google Scholar 

  24. Schauer IG, Ressler SJ, Tuxhorn JA, Dang TD, Rowley DR (2008) Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology 72(1):205–213. doi:10.1016/j.urology.2007.11.083

    Article  PubMed Central  PubMed  Google Scholar 

  25. Feneley MR, Span PN, Schalken JA, Harper M, Griffiths K, Holmes K, Kirby RS (1999) A prospective randomized trial evaluating tissue effects of finasteride therapy in benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2(5/6):277–281. doi:10.1038/sj.pcan.4500377

    Article  CAS  PubMed  Google Scholar 

  26. Gharaee-Kermani M, Kasina S, Moore BB, Thomas D, Mehra R, Macoska JA (2012) CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis. PLoS ONE 7(11):e49278. doi:10.1371/journal.pone.0049278

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Bjork J, Grubb A, Larsson A, Hansson LO, Flodin M, Sterner G, Lindstrom V, Nyman U (2014) Accuracy of GFR estimating equations combining standardized cystatin C and creatinine assays: a cross-sectional study in Sweden. Clin Chem Lab Med. doi:10.1515/cclm-2014-0578

    PubMed  Google Scholar 

  28. Bouchelouche K, Alvarez S, Andersen L, Nordling J, Horn T, Bouchelouche P (2004) Monocyte chemoattractant protein-1 production by human detrusor smooth muscle cells. J Urol 171(1):462–466

    Article  CAS  PubMed  Google Scholar 

  29. Desireddi NV, Campbell PL, Stern JA, Sobkoviak R, Chuai S, Shahrara S, Thumbikat P, Pope RM, Landis JR, Koch AE, Schaeffer AJ (2008) Monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha as possible biomarkers for the chronic pelvic pain syndrome. J Urol 179(5):1857–1861. doi:10.1016/j.juro.2008.01.028 discussion 1861–1852

    Article  PubMed Central  PubMed  Google Scholar 

  30. Vicentini C, Gravina GL, Angelucci A, Pascale E, D’Ambrosio E, Muzi P, Di Leonardo G, Fileni A, Tubaro A, Festuccia C, Bologna M (2004) Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer from benign prostatic hyperplasia. J Cancer Res Clin Oncol 130(4):217–221. doi:10.1007/s00432-003-0525-8

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The work was partly supported by grants; NIH P20 DK090919, NIH R01CA12060, NIH R01DK087962 (PI Fowke).

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Urology, University of Pittsburgh, E313 Montefiore Hospital, 3459 Fifth Ave, Pittsburgh, PA, 15213, USA

    Pradeep Tyagi, Mahendra Kashyap, Subrata Pore, Jeffrey Gingrich, Zhou Wang & Naoki Yoshimura

  2. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37032, USA

    Saundra S. Motley & Jay H. Fowke

  3. Department of Surgical Urology, Vanderbilt University Medical Center, Nashville, TN, 37032, USA

    Jay H. Fowke

Authors
  1. Pradeep Tyagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saundra S. Motley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mahendra Kashyap
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Subrata Pore
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jeffrey Gingrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhou Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naoki Yoshimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jay H. Fowke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pradeep Tyagi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tyagi, P., Motley, S.S., Kashyap, M. et al. Urine chemokines indicate pathogenic association of obesity with BPH/LUTS. Int Urol Nephrol 47, 1051–1058 (2015). https://doi.org/10.1007/s11255-015-0992-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-015-0992-2

Keywords

Search

Navigation